Kornimate/medical-research-clean huggingface dataset:
efficacy of retinal nerve fiber layer (rnfl) / ganglion cell layer thickness ratio by rt-view utilizing spectral -domain technology as a diagnostic predictor of glaucoma.

Conditions: Primary Open Angle Glaucoma

Summary: rt-view utilizes spectral domain technology to assess both rnfl and ganglion cell layer thickness. this study aims to correlate visual field defects in patients with glaucoma to both rnfl and ganglion cell layer thickness.


Eligibility criteria:
exclusion criteria: * evidence of retinal disease * neovascular glaucoma * secondary glaucoma due to intraocular inflammation * lens induced glaucoma * tumor induced glaucoma

Keywords: rt-view spectral domain oct ganglion cell layer rnfl visual field defect
recombinant factor viia (novoseven) on restoring coagulation activation

Conditions: Hemophilia A

Summary: the purpose of the study is to compare the effects of recombinant factor viia (novoseven) on restoring coagulation activation between patients with hemophilia a and antibodies to factor viii and normal subjects (controls) by use of an in vivo method.


Eligibility criteria:
inclusion criteria: * adult patients with hemophilia a and current antibodies to factor viii - exclusion criteria: * life-threatening hemorrhage * severe liver failure * any other severe co-morbidity (including diabetes mellitus, renal failure, cancer, septicemia, disseminated intravascular coagulation, crush injury) * exposure to other haemostatic drugs during the previous 7 days * hypersensitivity to hamster, mouse or bovine proteins * known or suspected allergy to novoseven or any of its components

Keywords: factor viii inhibitor
a dose-finding and exploratory study of ro5323441 in combination with sorafenib in patients with hepatocellular carcinoma

Conditions: Carcinoma, Hepatocellular

Summary: this open-label study will assess the safety, efficacy and pharmacokinetics of ro5323441 in combination with sorafenib in patients with advanced or metastatic hepatocellular carcinoma previously untreated with systemic therapy. in the dose-finding part i, cohorts of patients will receive escalating doses of ro5323441 intravenously (iv) every 2 weeks in combination with sorafenib 400 mg orally twice daily. in the exploratory part ii, patients will be randomized to receive either the previously established dose of ro5323441 iv every 2 weeks plus continuous oral sorafenib or sorafenib alone. anticipated time on study treatment is until disease progression or unacceptable toxicity occurs. for patients in the sorafenib arm with disease progression crossover to combination treatment with ro5323441 will be allowed.


Eligibility criteria:
inclusion criteria: * adult patients \>/= 21 years of age * advanced or metastatic and/or unresectable hepatocellular carcinoma * at least 1 measurable lesion according to recist criteria * primary tumor in situ (expansion cohort part i, part ii) * eastern cooperative oncology group (ecog) performance status 0-1 * adequate bone marrow, liver and renal function exclusion criteria: * prior systemic treatment for metastatic hepatocellular carcinoma or patients who had tumor removed (expansion cohort part i, part ii) * major surgery within previous 4 weeks or planned major surgical procedure during course of study * radiation therapy within 28 days prior to start of study treatment * serious non-healing wound, ulcer ore bone fracture * history of uncontrolled seizures or encephalopathy within the last 6 months * current central nervous system (cns) metastases or spinal cord compression * history of gastrointestinal perforation or esophageal/gastric bleeding within 6 months prior to study enrollment * history of another primary malignancy and off treatment for \</= 3 years, except for non-melanoma skin cancer and carcinoma in situ of the cervix * patients with prior liver transplant * inadequately controlled hypertension or prior history of hypertensive crisis or hypertensive encephalopathy * active bleeding diathesis
clinical & radiographical evaluation of the effect of dycal & biodentine in dpc in primary teeth

Conditions: Dental Pulp Exposure

Summary: the purpose of this study was clinical and radiographical evaluation of the effect of calcium hydroxide cement (dycal) and calcium silicate cement (biodentine) in direct pulp capping in primary teeth.

the aim of the present study is to compare calcium hydroxide cement (dycal) ® and calcium silicate cement (biodentine)tm as pulp capping agents in primary molars. the objective of this study include the evaluation of clinical and radiographic efficacy of calcium hydroxide cement (dycal) ® and calcium silicate cement (biodentine)tm, and their response in direct pulp capping treatment on primary molars during a 6 months follow up. after following the proper standardized procedure for direct pulp cap. in the current study direct pulp capping was performed using calcium hydroxide cement (dycal)® and calcium silicate cement (biodentine)tm on 60 primary teeth of children equally divided between 2 study groups randomly of both the sexes aged 4-9 years old. complete case history was recorded in detail and intraoral periapical radiograph was also taken for teeth indicated for direct pulp capping. written consent was obtained from the parents of participants before starting the procedure. strict standardized procedure had been followed and the pulp capping agent (dycal®/biodentinetm) were applied according to the manufacturer's instructions.each patient was evaluated clinically and radiographically for any abnormal clinical signs and symptoms at 1,3 and 6 months postoperatively.better results for the success of the study could be relatively enhanced by close attention to rigid criteria for case selection, standardization of direct pulp capping procedure and meticulous performance of the procedure appear to be prerequisites for successful treatment.

Eligibility criteria:
inclusion criteria: 1. good health. 2. cooperative behaviour. 3. informed consent from parents. 4. primary molars with clinically active caries. 5. no history of spontaneous pain in teeth. 6. restorable tooth with at least one half of root length present. 7. absence of pathological mobility. 8. absence of tenderness to percussion. 9. normal gingiva and periodontal condition without the sign of pathology such as redness and swelling of vestibule, draining sinus tract or sensitivity to palpate in the vestibule. in addition, the teeth treated by direct pulp capping had only a pin point mechanical exposure (0.5 to 1mm), for which haemorrhage control could be achieved within two minutes before proceeding with direct pulp capping. radiographically, there was absence of internal resorption, external resorption, periapical or furcation radiolucencies and pathology of succedenous permanent tooth follicle. exclusion criteria: * patients with a history of spontaneous pain, tooth tender to percussion, absence of underlying permanent teeth, internal/external root resorption, apical/furcal lesions, sinus tract, physiologic or pathologic luxation, and/or presence of abscess were excluded from the study.
3-dimensional sensor technology to quantify leg-edema

Conditions: ADHF

Summary: the purpose of the study is two-fold: 1. to test 3-dimensional reconstruction of leg-edema in patients hospitalized for acute heart failure with leg-edema. 2. to measure changes in qrs-morphology in a simulation of conventional blood-pressure measurement in patients hospitalized for acute heart failure.

leg-edema are common in patients with worsening heart failure. apart from using a measuring tape there is no standardized tool to quantify leg-edema. consequently, in patents with heart failure early detection of leg-edema is quite difficult. from earlier pacemaker-studies it has been shown that an increase of afterload changes ecg-signals. currently it is unknown how simple diagnostic procedures such as measuring blood-pressure affect qrs-morphology in patients with heart failure.

Eligibility criteria:
inclusion criteria: * hospitalization for worsening heart failure * age greater than 18 years * ability to stand without help from others * informed consent exclusion criteria: * leg-edema of non-cardiac origin (venous, lymphatic) * dialysis shunt

Keywords: acute heart failure
psychometric properties of the elderly health questionnaire among community-dwelling older people

Conditions: Frailty

Summary: the aims of this study are to validate the reliability and validity of elderly health questionnaire in assessing frailty risk of community-dwelling older adults.

the aims of this study are to validate the test-retest reliability, internal consistency, criterion-related validity, predictive validity and construct validity of elderly health questionnaire in assessing frailty risk of community-dwelling older adults. the investigators conduct a prospective study to require data of health states, function, lifestyle and quality of life in community-dwelling older adults ,and will recruit about 150 subjects in ntuh and communities in taipei city. the investigators analyze the (change) scores of elderly health questionnaire to test the internal consistency and test-retest reliability. also, the investigators test the correlation between the scores of elderly health questionnaire and the scores of the other measurements (i.e., help-t, whoqol-bref, moca, sppb, upsa-b) to validate the concurrent validity, and the correlation between the scores of elderly health questionnaire and the scores of cfs to validate predictive validity. the construct validity is validated by exploratory factor analysis.

Eligibility criteria:
inclusion criteria: * aged \> 65 years old * able to read * clinical frailty scale ≦ 6 exclusion criteria: * diagnosed as dementia or schizophrenia * active cancer receiving treatment * terminal cancer patient * hospitalization in 1 month * with implantable device * couldn't follow the instructions * wheelchair bound

Keywords: frailty older adults instrument community
comparison of minimal effective dose of sucrose for pain relief in neonates after minor procedure

Conditions: Post Procedural Pain Management in Neonates

Summary: type of study: randomized controlled trial aim: to compare the effectiveness of two doses of sucrose solution for pain relief in neonates after minor procedures. participants' tasks: receive either 0.2 ml or 0.5 ml of sucrose solution. undergo minor procedures. pain intensity assessment using the premature infant pain profile (pipp). comparison groups: researchers compared the effects of administering 0.2 ml and 0.5 ml doses of sucrose solution on post-procedural pain in neonates.

this study is a randomized controlled trial conducted at the department of pediatric surgery, holy family hospital, rawalpindi, from march 2023 to february 2024. it aims to compare the effectiveness of two different doses of sucrose solution (0.2 ml versus 0.5 ml) for pain relief in neonates after minor procedures. objective: to compare the outcome of 0.2 ml versus 0.5 ml sucrose solution for pain relief in neonates after minor procedures. study design: randomized controlled trial study place and duration: department of pediatric surgery, holy family hospital, rawalpindi, march 2023 to february 2024. participants and methods: total of 148 neonates enrolled who underwent minor procedures and were admitted to the neonatal intensive care unit. randomly divided into two groups: group i: administered 0.2 ml of sucrose solution group ii: administered 0.5 ml of sucrose solution pain intensity measured using the premature infant pain profile (pipp). data analyzed using spss version 25.0.

Eligibility criteria:
inclusion criteria: * healthy term neonates admitted to the neonatal intensive care unit (nicu) and high dependency unit (hdu) at the department of pediatric surgery, holy family hospital, rawalpindi. exclusion criteria: * neonates with contraindications for sucrose administration, including: inability to swallow. pharmacological muscle relaxation. heavy sedation. neonates who are unable to clearly view the infant's face, hindering accurate pain assessment

Keywords: sucrose solution, pain relief, neonates, minor procedure, premature infant pain profile
get with the guidelines-stroke registry

Conditions: Stroke

Summary: get with the guidelines-stroke is a program for improving the quality of care for patients hospitalized with stroke by promoting consistent adherence to the latest evidence-based clinical practice guidelines.

get with the guidelines®-stroke is an in-hospital program for improving stroke care by promoting consistent adherence to the latest scientific treatment guidelines. since its initiation in 2003, 2,637 hospitals have entered 3,892,063 patient records into the get with the guidelines-stroke database. numerous published studies demonstrate the program's success in achieving measurable patient outcome improvements. achievement measures tracked through the get with the guidelines®-stroke: * iv rt-pa arrive by 3.5 hour, treat by 4.5hour * early antithrombotics * vte prophylaxis * antithrombotics at or by discharge * anticoagulation for afib/aflutter at or by discharge * smoking cessation at or by discharge * intensive statin therapy quality measures tracked through the get with the guidelines®-stroke: * dysphagia screen * time to intravenous thrombolytic therapy-60 min * nihss reported * stroke education at or by discharge * rehabilitation considered at or by discharge * ldl documented additional measures collected by get with the guidelines®-stroke can be viewed at: https://www.heart.org/en/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/get-with-the-guidelines-stroke-patient-management-tool

Eligibility criteria:
inclusion criteria: * patients presented with a diagnosis of ischemic stroke or transient ischemic attack, subarachnoid hemorrhage, intracerebral hemorrhage, or stroke not otherwise specified to the hosptials. exclusion criteria: * patients who do not have a diagnosis of ischemic stroke or transient ischemic attack, subarachnoid hemorrhage, intracerebral hemorrhage, or stroke not otherwise specified. * patients under age of 18

Keywords: stroke
effect of continuous positive airway pressure treatment on inflammation in patients with obstructive sleep apnea

Conditions: Obstructive Sleep Apnea; Inflammation; Continuous Positive Airway Pressure

Summary: the purpose of this study is to evaluate the effects of cpap treatment on airway and systemic inflammation in obstructive sleep apnea.

obstructive sleep apnea (osa) is characterised by repetitive episodes of upper airway obstruction during sleep. systemic and airway inflammation has been recently shown to be associated with osa and is hypothesized to contribute to the clinical manifestation and the complications of osa patients. continuous positive airway pressure (cpap) is a first-line treatment for osa and improves diurnal and nocturnal symptoms. however, the effectiveness of cpap in reversing airway inflammation is less compelling in comparison to systemic inflammation. this study will assess no in exhaled breath, inflammatory biomarkers in induced sputum and blood of osa patients and other clinical measurements before and after 3 months of cpap treatment.

Eligibility criteria:
inclusion criteria: * subjects on admission for sleep study under the respiratory care and sleep control medicine, kyoto university hospital. * subjects diagnosed with osa (apnea hypopnea index \>=20/hour) by overnight polysomnography. exclusion criteria: * known history of respiratory diseases that will affect airway inflammatory markers like asthma, chronic obstructive pulmonary disease and bronchiectasis. * treatments with corticosteroids or other immunosuppressive drugs.
extraction of the compromised first permanent molars

Conditions: Caries; Caries,Dental

Summary: compromised first permanent molars (fpm), whether diagnosed with severe molar incisor hypomineralization (mih), irreversible pulpities, or necrosis, require frequent re-treatment consequently entering the restorative cycle, which leads to their inevitable extraction and implant placement. extraction of compromised first permanent molars in 8-10-year-old children allows the mesial migration of the second permanent molars during their eruption, thereby favoring spontaneous space closure as a permanent solution.

extraction of compromised first permanent molars in children decreases the burden of repeated restorative procedures for theses molars, which will eventually need frequent repair. this will end in their inevitable extraction with its consequences. the extraction of the fpm will be delivered by nour wahba, dina darwish, and basma nagi, lecturers in pediatric dentistry and dental public health department, faculty of dentistry, ain shams university.all patients will be recalled for follow-up yearly for three-years. the first follow-up will be done after 6months to perform the quality of life questionnaires. the position of the second permanent molar will be checked clinically and radiographically to evaluate the space between second premolar and the second molar.

Eligibility criteria:
inclusion criteria: * healthy patients\&#39; class i according to the american society of anesthesiologists (asa class i) * age: 8-10 years * angle class i occlusion * the radiographic presence of the second premolar * the radiographic stages of development e or f for formation the second permanent molar. * first permanent molar that is severely affected by mih, signs of necrosis, signs of irreversible pulpitis or non-restorability. exclusion criteria: * refusal of the parents to sign the informed consent. * signs of reversible pulpitis of first permanent molar. * patients with severe malocclusion.

Keywords: first permanent molar molar incisor hypo mineralization dental extraction space closure
comparison of two medication adherence strategies to improve asthma treatment adherence

Conditions: Asthma; Lung Diseases

Summary: this is a randomized, controlled study that will compare two medication adherence strategies in adults with moderate or severe persistent asthma as a method for improving or maintaining treatment adherence.

low-income minority adults have excessively high rates of morbidity from asthma. poor medication adherence has been documented in these individuals and contributes to the high morbidity level. this study will compare a problem solving intervention with an attention control intervention to improve and sustain asthma self-management in a clinical setting. this study will include strategies to address contextual factors related to adherence. participants will be recruited from clinics that serve minority and low-income individuals.

Eligibility criteria:
inclusion criteria: * receiving treatment for asthma at one of the participating clinics * moderate or severe persistent asthma according to the nhlbi guidelines * current use of prescribed inhaled corticosteroids * evidence of reversible airflow obstruction, as indicated by the following two criteria: 1. fev1pp and less than 80% at the time of study entry or within the 3 years prior to study entry 2. an increase of greater than 15% and 200ml in fev1 with asthma treatment over the last 3 years (if there is no record of such improvement, participants will be evaluated via spirometry pre- and post-bronchodilator at the first study visit. an increase in fev1 or fvc greater than 12% and 200 ml in fev1 30 minutes following albuterol administration will represent evidence of reversible airflow obstruction. if a spirometer is not immediately available, participants may be evaluated using a peak flow meter, which reports a pef. a pefpp less than 80% and an improvement of at least 60 l per minute after the administration of albuterol will represent evidence of reversible airflow obstruction) * has a functional telephone or mobile phone exclusion criteria: * significant lung or cardiac disease (other than hypertension) * psychiatric illness, such as mania or schizophrenia, that may make it impossible to understand or carry out the problem solving intervention
safety and efficacy study of bdb-001 injection in patients with moderate to severe hidradenitis suppurativa (hs)

Conditions: Hidradenitis Suppurativa

Summary: a study to explore the safety and efficacy of treatment with bdb-001 injection in adults with moderate to severe hidradenitis suppurativa (hs).


Eligibility criteria:
inclusion criteria: * 18 years old≤age≤65 years old, male or female; * diagnosis of hs for at least 6 months; * hs lesions must be present in at least two distinct anatomical areas, one of which must be at least located in the apocrine sweat gland area and hurley stage ii or hurley stage iii; * total abscess and inflammatory nodule (an) count of ≥ 3. exclusion criteria: * subject was previously treated with adalimumab or another biologic product during the 3 months before the first administration; * subject received any oral antibiotic treatment for hs within 2 weeks before the first administration; * subject received any oral retinoids treatment for hs within 4 weeks before the first administration; * subject received oral opioids analgesics within 1 week before the first administration; * systematic treatment with glucocorticoid or intramural injection within 4 weeks before the first administration; * history of heart disease or malignancy.
immunological mechanisms of oralair® in patients with seasonal allergic rhinitis

Conditions: Allergic Rhinitis

Summary: allergic diseases represent a major health issue worldwide and epidemiological studies in melbourne, australia, have reported a high prevalence of rhinitis (hayfever) and atopy (genetic tendency to make allergy antibody) in asian and caucasian subjects. mainstay treatment of allergic rhinitis is allergen avoidance and pharmacotherapy for symptom relief. allergen immunotherapy offers the advantages of specific treatment with long lasting efficacy, and can modify the course of disease. however, use of this treatment is restricted by the high risk of adverse events especially in asthmatics. other, better tolerated, routes of allergen administration than the current conventional subcutaneous route (scit) have been investigated including the sublingual route (slit) and recently sublingual tablets for pollen allergy immunotherapy became available. the tablets are safe and easy to use and contain pollen extracts from 5 of the most common allergy-causing european grasses but include ryegrass (lolium perenne), the major seasonal pollen for allergy in melbourne and south-eastern australia. the immunological mechanisms of sublingual immunotherapy are not fully understood. the investigators propose conducting a longitudinal open label study to investigate the immunological changes that occur with the 5 grass pollen sublingual immunotherapy tablet (oralair®) in a cohort of chinese and non-chinese background subjects. the investigators will investigate the induction of relevant t cell regulatory immune mechanisms and changes in serum allergen-specific immunoglobulin (ig) e and igg4. immunoregulatory cytokine synthesis and t cell phenotype (bio-plex and flow cytometry) will be examined. this project will provide important fundamental knowledge on which to inform decisions for the greater application of this treatment for subjects with moderate and severe allergic rhinitis.


Eligibility criteria:
inclusion criteria: * subjects of chinese heritage or non-chinese heritage * clinical diagnosis of moderate to severe seasonal allergic rhinitis * ryegrass-specific ige : cap-pharmacia score \> 1 exclusion criteria: * ongoing immunotherapy or previous immunotherapy (within last 5 years) * continuous oral corticosteroids * moderate, severe or unstable asthma * standard contraindications for allergen immunotherapy * ongoing treatment with β-blockers * immunodeficiency diseases * malignancy * significant inflammatory condition or disease in the oral cavity

Keywords: allergic rhinitis asthma regulatory t cells ige igg4